Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Ben…

MIAMI–(BUSINESS WIRE)—- $SMMT–Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the novel, potential first-in-class…


Click here to view the original article.